AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

As of Thursday’s close, the S&P 500 has a week-to-date gain of nearly 4%, the Dow Jones Industrial Average is up more than 2% ...

AbbVie has kicked off the year with a resounding success, exceeding expectations across multiple therapeutic areas. The ...

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales ...

While management did not quantify any potential tariff exposure, it did signal that the effect would be in line with the ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...